Pain-relieving prospects for adenosine receptors and ectonucleotidases - PubMed (original) (raw)
Review
Pain-relieving prospects for adenosine receptors and ectonucleotidases
Mark J Zylka. Trends Mol Med. 2011 Apr.
Abstract
Adenosine receptor agonists have potent antinociceptive effects in diverse preclinical models of chronic pain. By contrast, the efficacy of adenosine and adenosine receptor agonists in treating pain in humans is unclear. Two ectonucleotidases that generate adenosine in nociceptive neurons were recently identified. When injected spinally, these enzymes have long-lasting adenosine A(1) receptor-dependent antinociceptive effects in inflammatory and neuropathic pain models. Furthermore, recent findings indicate that spinal adenosine A(2A) receptor activation can enduringly inhibit neuropathic pain symptoms. Collectively, these studies suggest the possibility of treating chronic pain in humans by targeting specific adenosine receptor subtypes in anatomically defined regions with agonists or with ectonucleotidases that generate adenosine.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Proteins that regulate extracellular adenosine levels also influence adenosine receptor activation. (a). ATP can be released from neurons and/or glial cells by vesicular and non-vesicular mechanisms. Vesicular nucleotide transporter (VNUT/ SLC17A9), volume activated anion channels (VAAC), Connexin 43 (Cx43). Ectonucleotidases (pacman-like symbol) hydrolyze extracellular nucleotides to adenosine. Adenosine acts on adenosine receptors, including A1R. Sustained A1R activation reduces PIP2 levels and has antinociceptive effects in animals. Adenosine is removed from the extracellular space by metabolic enzymes or by transport into cells via equilibrative nucleoside transporters (ENTs). AMP deaminase metabolizes AMP to inosine monophosphate (IMP). Blue = proteins linked to nociceptive mechanisms by genetic experiments. (b). Structures of 5’-AMP and adenosine.
Similar articles
- Recombinant ecto-5'-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation.
Sowa NA, Voss MK, Zylka MJ. Sowa NA, et al. Mol Pain. 2010 Apr 14;6:20. doi: 10.1186/1744-8069-6-20. Mol Pain. 2010. PMID: 20398264 Free PMC article. - PAP and NT5E inhibit nociceptive neurotransmission by rapidly hydrolyzing nucleotides to adenosine.
Street SE, Walsh PL, Sowa NA, Taylor-Blake B, Guillot TS, Vihko P, Wightman RM, Zylka MJ. Street SE, et al. Mol Pain. 2011 Oct 19;7:80. doi: 10.1186/1744-8069-7-80. Mol Pain. 2011. PMID: 22011440 Free PMC article. - Ecto-5'-nucleotidase (CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive circuits.
Sowa NA, Taylor-Blake B, Zylka MJ. Sowa NA, et al. J Neurosci. 2010 Feb 10;30(6):2235-44. doi: 10.1523/JNEUROSCI.5324-09.2010. J Neurosci. 2010. PMID: 20147550 Free PMC article. - Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.
Vincenzi F, Pasquini S, Borea PA, Varani K. Vincenzi F, et al. Int J Mol Sci. 2020 Nov 18;21(22):8710. doi: 10.3390/ijms21228710. Int J Mol Sci. 2020. PMID: 33218074 Free PMC article. Review. - Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs.
Akkari R, Burbiel JC, Hockemeyer J, Müller CE. Akkari R, et al. Curr Top Med Chem. 2006;6(13):1375-99. doi: 10.2174/15680266106061375. Curr Top Med Chem. 2006. PMID: 16918456 Review.
Cited by
- Electroacupuncture Relieves Neuropathic Pain via Adenosine 3 Receptor Activation in the Spinal Cord Dorsal Horn of Mice.
Kiani FA, Li H, Nan S, Li Q, Lei Q, Yin R, Cao S, Ding M, Ding Y. Kiani FA, et al. Int J Mol Sci. 2024 Sep 24;25(19):10242. doi: 10.3390/ijms251910242. Int J Mol Sci. 2024. PMID: 39408573 Free PMC article. - TRPA1, TRPV1, and Caffeine: Pain and Analgesia.
Puthumana EA, Muhamad L, Young LA, Chu XP. Puthumana EA, et al. Int J Mol Sci. 2024 Jul 19;25(14):7903. doi: 10.3390/ijms25147903. Int J Mol Sci. 2024. PMID: 39063144 Free PMC article. Review. - Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition.
Kenakin T. Kenakin T. Nat Rev Drug Discov. 2024 Aug;23(8):626-644. doi: 10.1038/s41573-024-00958-9. Epub 2024 Jun 18. Nat Rev Drug Discov. 2024. PMID: 38890494 Review. - Analgesic candidate adenosine A 3 receptors are expressed by perineuronal peripheral macrophages in human dorsal root ganglion and spinal cord microglia.
Sapio MR, Staedtler ES, King DM, Maric D, Jahanipour J, Ghetti A, Jacobson KA, Mannes AJ, Iadarola MJ. Sapio MR, et al. Pain. 2024 Oct 1;165(10):2323-2343. doi: 10.1097/j.pain.0000000000003242. Epub 2024 Apr 30. Pain. 2024. PMID: 38691673 - Antinociceptive Analysis of Natural Monoterpenes Eugenol, Menthol, Carvacrol and Thymol in a Zebrafish Larval Model.
Rocha CA, Félix LM, Monteiro SM, Venâncio C. Rocha CA, et al. Pharmaceuticals (Basel). 2024 Apr 2;17(4):457. doi: 10.3390/ph17040457. Pharmaceuticals (Basel). 2024. PMID: 38675417 Free PMC article.
References
- Schulte G, et al. Distribution of antinociceptive adenosine A1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations. Neuroscience. 2003;121:907–16. - PubMed
- Reppert SM, et al. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol. 1991;5:1037–48. - PubMed
- Lima FO, et al. Direct blockade of inflammatory hypernociception by peripheral A1 adenosine receptors: Involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain. 2010;151:506–515. - PubMed
- Sawynok J. Adenosine and ATP receptors. Handb Exp Pharmacol. 2007;177:309–28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 NS067688-01/NS/NINDS NIH HHS/United States
- R01 NS060725/NS/NINDS NIH HHS/United States
- R01 NS060725-02/NS/NINDS NIH HHS/United States
- R01 NS067688-03/NS/NINDS NIH HHS/United States
- R01 NS067688-02/NS/NINDS NIH HHS/United States
- R01 NS060725-03/NS/NINDS NIH HHS/United States
- R01NS067688/NS/NINDS NIH HHS/United States
- R01 NS067688/NS/NINDS NIH HHS/United States
- R01NS060725/NS/NINDS NIH HHS/United States
- R01 NS060725-01/NS/NINDS NIH HHS/United States
- R01 NS060725-04/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources